Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.

Revenue
+9.98%
EPS
+29.4%
Free cash flow
+6.21%
Total debt
−2.20%

Quarter to September 2026, against a year earlier

255.57 0.83 +0.33%
Market cap
$28.0B
P/E
25.0×
Fwd P/E
24.4×
Dividend yield
1.33%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
7 8 8 7

+8 more TTM periods

ROE
14.76% 14.03% 13.95% 14.10%
ROA
6.73% 6.43% 6.28% 6.10%
ROIC
8.48% 7.94% 7.78% 7.81%
Return on Tangible Assets
31.62% 32.31% 39.57% 42.90%
Average Days of Receivables
52.77 52.60 51.36 46.57
Free Cash Flow per Share
12.50 12.15 12.05 12.24
Free Cash Flow
1,375.00 1,349.00 1,326.00 1,359.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026